PTAB Need Not Address Underdeveloped Arguments in IPR Petitions
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Emily K. McCorry & Jeremy Anapol
Before Dyk, Linn, and Chen. Appeal from the Patent Trial and Appeal Board.
Summary: The PTAB did not abuse its discretion by declining to address arguments that an IPR petitioner failed to clearly raise in its petitions.
Netflix requested inter partes review of two patents assigned to DivX. The Patent Trial and Appeal Board (“PTAB”) found that Netflix failed to prove the challenged claims unpatentable. Netflix appealed, contending that the PTAB overlooked or misinterpreted several arguments in Netflix’s petitions.
The Federal Circuit reviewed the decisions below, including the PTAB’s interpretation of Netflix’s petitions, for abuse of discretion. Because the arguments Netflix raised on appeal were not clearly present in the petitions, and the PTAB did not clearly misinterpret them, the Federal Circuit affirmed.
Judge Dyk dissented, arguing that Netflix’s petitions properly presented some of the arguments that Netflix raised on appeal.
Editor: Sean Murray
More insights
PTAB in 2026: What Practitioners Are Getting Wrong
Institution rates have moved, but the reasoning behind them has moved further. The number most petitions still cite is the headline institution rate — and it has not been the operative number for two years. The two stage problem A petition now has to…
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…